Unusual radiologic manifestation of pseudoprogression in pulmonary metastases after durvalumab treatment in metastatic bladder urothelial cancer.
Eun Young KimInkeun ParkYoung Saing KimHee Kyung AhnHee Young LeeJeong Ho KimPublished in: Thoracic cancer (2019)
Durvalumab is an immune checkpoint inhibitor that blocks PD-L1. Unlike cytotoxic chemotherapy or molecularly targeted agents, immune checkpoint inhibitors occasionally present distinct response patterns, including radiologic pseudoprogression (initial tumor enlargement with subsequent tumor regression) and immune-related adverse events in normal tissues. We report a case of unusual computed tomography (CT) findings of pseudoprogression of pulmonary metastases in a patient with metastatic bladder cancer after durvalumab treatment: multiple pulmonary metastases turned into ground-glass opacity on first follow-up CT; on second follow-up CT, and after sustained treatment of the PD-L1 inhibitor, the lesion was resolved.
Keyphrases
- computed tomography
- pulmonary hypertension
- squamous cell carcinoma
- small cell lung cancer
- contrast enhanced
- dual energy
- image quality
- positron emission tomography
- magnetic resonance imaging
- gene expression
- spinal cord injury
- magnetic resonance
- combination therapy
- drug delivery
- replacement therapy
- cancer therapy
- pet ct